<DOC>
	<DOCNO>NCT00682786</DOCNO>
	<brief_summary>Determine genotype-directed neoadjuvant chemoradiation , use information thymidylate synthase promoter polymorphism , result great degree tumor downstaging high risk patient compare historical control .</brief_summary>
	<brief_title>Genotype-directed Neoadjuvant Chemoradiation Rectal Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Rectal Neoplasms</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>Biopsy proven adenocarcinoma rectum Lesion evaluate surgeon find resectable Stage T3 T4 disease radiography ultrasound Karnofsky Performance Status &gt; 60 Laboratory criterion : Absolute neutrophil count &gt; = 1.5 K Platelets &gt; = 100 K Total Bilirubin &lt; = 2.0 ; SGOT Alkaline Phosphatase &lt; = 2 x upper limit normal Creatinine &lt; 2.0 Informed consent sign Patients distant metastatic disease eligible satisfy condition . Pregnant woman , child &lt; 18 year , patient unable give inform consent Patients past history pelvic radiotherapy . Patients prior malignancy past 5 year except : skin cancer insitu cervical cancer . However , patient synchronous adenocarcinoma eligible provide either ( ) synchronous adenocarcinoma remove pedunculated polyp invade stalk ( b ) synchronous adenocarcinoma remove polyp lay within surgical field ( extent resection would change ) ( c ) synchronous adenocarcinoma small index rectal cancer lie completely within radiation field ( clinically favorable second lesion extend radiation surgery would change ) . Patients know allergy 5fluorouracil irinotecan</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>rectal</keyword>
	<keyword>rectum</keyword>
	<keyword>cancer</keyword>
	<keyword>carcinoma</keyword>
</DOC>